

AMPLICON PREMIERES PRODUCTS ON WORLD'S LARGEST NICOTINE FORUM

Amplicon will premiere two products at the Global Forum on Nicotine, which will be held in Warsaw on 16-18 June 2022. The world's largest annual conference in the tobacco and nicotine industry attracts a large number of visitors with experts, media, consumers, and industry professionals from many countries.

In Warsaw, Amplicon will present two dry white nicotine pouches with newly developed profiles for how flavor and nicotine are released. The technology is based on Amplicon's IP, based on ceramic biomaterials, and is a completely new generation of nicotine products with unique properties for a better user experience.

The theme of this year's conference, 'Tobacco Harm Reduction - here for good', is fully in line with the products that Amplicon is developing within the Amp01 project.

"We have conducted tests with very good results and we look forward to receiving the international response at the forum," says Tomas Hammargren, Chairman of Amplicon.

GFN22 explores the science of safer products and addresses the changes in policies and regulations needed to maximize their potential. Although most of the restrictions on COVID-19 have been removed in many countries, the conference will also be broadcast live, via the FGN platform.

GFN is the only international conference that focuses on the important role that safer nicotine products have in helping people quit smoking. Safer nicotine products include e-cigarettes (so-called vapes), nicotine pouches, oral tobacco, such as Swedish snus, and heated tobacco products. <https://gfn.events>

For more information, please contact:

Torbjörn W. Larsson

CEO

Phone: +46 (0) 70 747 65 99

Email: twl@emplicure.com

Erik Magnusson

CFO, Investor Relations

Phone: +46 (0) 708 565 245

Email: erik.magnusson@emplicure.com

Tomas Hammargren

Chairman, Amplicon AB

Phone: +46 (0) 706 494 549

Email: tomas.hammargren@amplic.se

This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on April 25, 2022 at 13:00 CET.



Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subsidiary, Amplicon AB develops consumer products, with oral nicotine as the first product. Emplicure is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com